Buy Singulair (Montelukast) Online — Merck Leukotriene Receptor Antagonist (LTRA) Oral Tablet for Asthma & Allergic Rhinitis

Singulair is the original brand name for montelukast sodium, an oral tablet taken once a day to prevent airway inflammation in asthma, to relieve nasal and eye symptoms in allergic rhinitis, and to prevent exercise-induced bronchoconstriction. It works by blocking a specific inflammatory messenger called cysteinyl leukotriene D4 at its receptor on airway and nasal tissue. Because it is a pill rather than an inhaler, Singulair has an outsized role for patients who cannot coordinate inhaler technique reliably, who dislike inhaler devices, or who need convenient control of allergic symptoms as well as asthma.

On this page you will find how the drug actually works, when clinicians use it, how the different formulations are dosed for adults and children, and most importantly what the FDA boxed warning about mood and behavior changes means for you or your child in practical terms. The information here follows the montelukast prescribing information, the March 2020 FDA Drug Safety Communication, the GINA and ARIA guidelines, and peer-reviewed randomised trials.

Because Singulair is used across such a wide age range — from a 12-month-old infant with mild asthma right through to an 80-year-old with allergic rhinitis — the sections that follow are organised by topic rather than by age. If your interest is limited to one formulation, use the section titles as a table of contents. If you want the full picture before starting the medicine, we recommend reading straight through, because the boxed-warning material in section 11 depends on understanding the mechanism and indications discussed earlier.

Singulair is a brand name that Merck registered in 1998 when the U.S. Food and Drug Administration approved the drug for the maintenance treatment of asthma in adults and paediatric patients aged six years and older. The active molecule inside the tablet is montelukast sodium, a chemically simple small molecule that survives passage through the stomach and small intestine and enters the bloodstream in high proportion. Since the original Merck patents expired, montelukast has become one of the most widely manufactured generic respiratory medicines in the world, and Indian producers such as Cipla and Sun Pharmaceutical Industries supply large volumes of it to regulated markets under their own trade names as well as under the shared generic label.

Calling montelukast an oral asthma medicine is technically correct but incomplete. Its full description in modern respiratory practice is a leukotriene receptor antagonist, and its regulatory approvals span three distinct clinical territories that are worth naming up front so the rest of this guide makes sense:

🍃 Chronic asthma control

Regular daily use to reduce airway inflammation, cut the frequency of daytime and night-time symptoms, and reduce reliance on rescue bronchodilators. Not a rescue medicine; it will not open an airway that is already tightening.

🌸 Allergic rhinitis relief

Reduction of runny nose, nasal congestion, sneezing, itching, and eye symptoms in patients with seasonal or perennial allergic rhinitis, either alone or alongside an intranasal steroid or a second-generation antihistamine.

🏃 Exercise-induced bronchoconstriction prevention

A single dose taken at least two hours before physical exertion, used by patients whose airways narrow during or after exercise. Distinct from the daily asthma use described above.

A useful mental shortcut is to think of Singulair as an oral controller. It sits alongside inhaled corticosteroids in the controller category of asthma medicines, not alongside albuterol or terbutaline in the reliever category. That framing determines everything about how it is prescribed, how quickly you should expect to feel a difference, and what happens if you miss a dose — topics we return to in later sections.

To use Singulair well and to understand why the boxed warning exists, it helps to spend two minutes on the biology of leukotrienes. Leukotrienes are a family of inflammatory signalling molecules made by white blood cells — principally mast cells and eosinophils — when they detect an allergen or an irritant. They are derived from arachidonic acid, a fatty acid found in the membranes of nearly every cell in the body, and they are synthesised through a chain of enzymes that starts with 5-lipoxygenase and ends with the release of cysteinyl leukotrienes into the surrounding tissue.

The three cysteinyl leukotrienes that matter clinically are named LTC4, LTD4, and LTE4. They travel short distances from the cell that made them and lock into a receptor on the surface of nearby cells — particularly airway smooth muscle cells, blood vessel walls in the airway lining, and mucus-secreting cells in both airway and nose. When these receptors are activated, three things happen almost simultaneously:

The single receptor responsible for all three effects is called CysLT1, and this is the receptor that montelukast blocks. By occupying CysLT1 and preventing the natural leukotrienes from docking, montelukast interrupts the signal before any of the three downstream consequences can occur. Notably it does not block the enzymes that make leukotrienes, so the leukotrienes are still produced — they simply cannot deliver their message. This distinction matters when you look at the safety profile, because the drug does not shut down the whole inflammatory system the way a corticosteroid does; it silences one specific channel.

There is a second receptor called CysLT2, mainly on blood vessel walls and some immune cells, which montelukast does not block. Whether CysLT2 activity contributes to residual symptoms in patients who respond only partially to Singulair is an active area of pharmacological research, and it is one reason a subset of patients feels only modest benefit from the drug.

The pharmacological label for montelukast is precise: it is a selective, orally active, high-affinity antagonist of the CysLT1 receptor. Every word in that label is doing work. Selective means it prefers CysLT1 over other leukotriene receptors and over unrelated receptors, so it does not scramble signalling in tissues that have nothing to do with allergy or asthma. Orally active means the molecule survives digestion and reaches the bloodstream intact, which is unusual for peptide-like signalling blockers and is one of the drug's main advantages over injectable biologics. High-affinity means one molecule of montelukast holds tightly to the receptor for a long time, which is the property that allows once-daily dosing.

The pharmacokinetic profile follows a predictable pattern that clinicians rely on when they counsel patients on timing:

A short half-life combined with high receptor affinity might seem contradictory — how can a drug leave the bloodstream in a few hours yet control symptoms for a full day? The answer is that receptor occupancy outlasts blood levels. Once a montelukast molecule binds CysLT1, it stays put long after the free drug in plasma has fallen. The receptor is, in effect, blocked for the interval between doses even though the drug itself is largely cleared by morning. This is why evening dosing works for adult asthma: peak plasma levels arrive during the late evening and overnight hours when airway inflammation is naturally at its worst, and residual receptor occupancy carries the effect into the following day.

The exclusively hepatic metabolism has a practical consequence. Kidney impairment, even severe kidney impairment, does not change montelukast handling and no dose reduction is needed. Moderate hepatic impairment (Child-Pugh Class A or B) also does not require dose adjustment in the product labelling. Only more severe hepatic impairment, which is uncommon in the outpatient asthma population, calls for caution — a topic we return to in the safety section.

Because Singulair covers three separate clinical territories, it is easy to get lost in what exactly the drug is licensed for and by what age. The table below summarises the U.S. FDA-approved indications and the minimum age for each formulation, so you can quickly see whether the medicine is being used within its licensed scope for the person taking it. In some countries the EMA and national regulators approve slightly different age thresholds, and the language on the local carton takes priority over any general summary.

A subtle but important point about the boxed warning: the 2020 FDA action narrowed the risk-benefit judgement for allergic rhinitis alone. The FDA now advises reserving Singulair for allergic rhinitis in patients who cannot tolerate or do not benefit from other treatments — typically an intranasal corticosteroid or a second-generation oral antihistamine. The asthma indications were not withdrawn, but the FDA emphasised that even for asthma the neuropsychiatric risk should be weighed against alternatives.

Nothing about the table above prevents off-label use, and clinicians sometimes prescribe montelukast for aspirin-exacerbated respiratory disease, chronic urticaria that has not responded to antihistamines, or bronchopulmonary dysplasia in premature infants. Those uses are not part of the licensed scope described here and do not carry the same evidence base.

Asthma prophylaxis was the original indication behind the 1998 approval, and it remains the single largest reason clinicians prescribe montelukast today. The word prophylaxis is important: it means the drug is taken every day to prevent symptoms, not taken during a symptom episode to reverse it. That places Singulair firmly in the controller category alongside inhaled corticosteroids, not in the reliever category alongside short-acting beta-agonists like albuterol or salbutamol.

Randomised controlled trials during the drug's registration programme established three consistent effects when montelukast is taken as monotherapy in patients with mild persistent asthma:

Head-to-head trials against low-dose inhaled corticosteroids consistently show that inhaled steroids produce a larger effect on lung function and on exacerbation rates when averaged across a population. That is why every major guideline — GINA, NAEPP, the British Thoracic Society — positions inhaled corticosteroids as the preferred controller for persistent asthma at any severity level. Montelukast is positioned as an alternative controller for patients who cannot or will not use an inhaler, or as an add-on to an inhaled corticosteroid when the inhaler alone is not enough.

The picture is different for patients with an allergic-rhinitis component, who often report that a single evening tablet controls both their nasal symptoms and their mild asthma more comfortably than juggling separate treatments. Trial data from mixed asthma-rhinitis populations show larger effect sizes than trials in asthma alone, partly because the pathophysiology is more leukotriene-driven and partly because adherence to a once-daily tablet is much better than adherence to a twice-daily inhaler in patients who dislike inhalers.

Real-world practice reflects that split. Adult patients with mild persistent asthma whose airway disease is heavily overlapped with allergic rhinitis are the ones most likely to be offered Singulair as first-line monotherapy. Adult patients with moderate or severe asthma without prominent allergic features are far more likely to be offered an inhaled corticosteroid first and to receive montelukast, if at all, as an add-on rather than as the sole controller.

Allergic rhinitis divides neatly into two clinical patterns: seasonal, driven by tree, grass, or weed pollens that appear at predictable times of year, and perennial, driven by dust mite, animal dander, cockroach, or mould antigens that are present year-round. Singulair holds approvals for both patterns, and the practical implications differ enough to be worth spelling out.

In seasonal allergic rhinitis, patients typically start montelukast a few days before the expected pollen peak and continue through the season. Placebo-controlled trials in seasonal disease show consistent reductions in a composite score of sneezing, runny nose, nasal congestion, and nasal itching, with the largest effect on nasal congestion — a symptom that responds poorly to oral antihistamines because histamine is not its main driver. Ocular symptoms such as itching, tearing, and redness also improve modestly.

In perennial allergic rhinitis, treatment is longer term and evening dosing tends to matter more because nasal symptoms are often worst at night and on waking. Data from dust-mite-driven perennial disease show that montelukast can be layered on top of an intranasal steroid to catch residual symptoms rather than being used instead of it. In practice most allergists reserve montelukast for perennial rhinitis when the more effective options have been tried and have fallen short.

The 2020 boxed warning changed how FDA and clinicians now think about allergic rhinitis specifically. The FDA advised that for allergic rhinitis alone, the risk-benefit balance often favours other treatments first and that montelukast should be reserved for patients who cannot tolerate or who do not respond to those alternatives. That advice does not apply to asthma, where the drug retains a broader role, and it does not mean the drug should not be used for rhinitis — only that the conversation about it should be a considered one.

Exercise-induced bronchoconstriction is airway narrowing that occurs during or shortly after physical exertion, most obviously during cold-weather exercise, endurance sports, or activities with high minute-ventilation such as running and cycling. It is caused in part by the drying and cooling of the airway lining as large volumes of air move rapidly across it, which triggers mast cells to release leukotrienes among other mediators. Because leukotrienes are directly involved, blocking them with montelukast has a rational mechanism of action against this specific problem.

The exercise-induced bronchoconstriction indication is different from the asthma-control indication in two important ways. First, the drug is taken at least two hours before planned exercise, not simply on a daily evening schedule. Second, patients who already take montelukast every evening for asthma control should not add a second dose before exercise — the daily dose already provides receptor blockade. A separate pre-exercise dose is only used when montelukast is being used for exercise-induced bronchoconstriction as a stand-alone indication.

The size of benefit varies. In placebo-controlled crossover trials, montelukast reduced the maximum drop in FEV1 during a standardised exercise challenge by roughly half in responsive patients, and shortened the recovery time to baseline lung function. About a third of patients showed a smaller response, and clinicians typically follow up after two to four weeks of use to decide whether to continue.

An honest note on positioning: the workhorse treatment for exercise-induced bronchoconstriction remains a short-acting inhaled beta-agonist taken 15-30 minutes before exercise. It works within minutes, its response rate is high, and it is inexpensive. Singulair is a second-line choice for patients who cannot tolerate or do not respond to the inhaled option, or who prefer an oral approach for lifestyle reasons.

Positioning Singulair within a specific patient's treatment plan takes some care because the drug has real strengths in some contexts and offers little advantage over cheaper or more effective alternatives in others. GINA, the Global Initiative for Asthma, updates its strategy document annually and consistently describes montelukast as an alternative controller option at every step of asthma care, meaning it is legitimate but not the first choice. What follows is a plain-language reading of where the drug earns its place.

None of these scenarios are hard rules. Individual patients often deviate from the population average, and a two-to-four-week trial with clear success criteria — night-time awakenings, rescue-inhaler use, nasal congestion — is a reasonable way to test the drug in a patient who lies on the border between fit and unfit.

What matters most is that Singulair is discussed alongside its alternatives, not in isolation. If your clinician has offered montelukast without at least mentioning the intranasal-steroid or inhaled-controller alternatives, that conversation is worth having before starting the medicine.

Because Singulair is one of the very few oral options in a therapeutic area dominated by inhalers, the trade-off between oral and inhaled routes is at the heart of the decision to use this drug. There is no universally correct answer — the right route depends on the patient, the specific indication, and the practical realities of daily life. What follows is a side-by-side reading of the trade-offs.

A useful way to read this table: the oral advantage is adherence and simplicity, and the inhaled advantage is direct airway delivery with less systemic exposure. Neither wins on every dimension. For patients who take medication reliably and can master an inhaler, an inhaled corticosteroid is usually the better asthma controller. For patients whose lives make an inhaler impractical or whose rhinitis is a bigger burden than their asthma, Singulair often earns its place.

The 2020 boxed warning has shifted this conversation somewhat. Where the choice used to be almost purely about efficacy and lifestyle fit, it now includes an explicit consideration of mental-health history and monitoring capacity, which we cover in the next section.

In March 2020 the U.S. Food and Drug Administration required a boxed warning — the strongest label warning the agency issues — to be added to montelukast. The warning states that Singulair can cause serious mental health side effects, including agitation, aggressive behaviour, depression, sleep disturbances, suicidal thoughts and actions, and other neuropsychiatric events. The FDA reached this decision after reviewing accumulated post-marketing reports, published pharmacovigilance analyses, and a series of pediatric case series that suggested a real and consistent, if uncommon, signal.

The clinical presentation of these events is variable, and part of the reason the signal took years to be recognised is that the symptoms overlap with common experiences at any age. A child who is more argumentative than usual, a teenager who is sleeping poorly, an adult who is more anxious — each of these could be caused by many things other than montelukast. What distinguishes a drug-related event is temporal onset after starting the medicine and, in many published cases, resolution after stopping it.

The absolute frequency of these events is low. Post-marketing analyses estimate serious neuropsychiatric events at less than one per thousand patient-years of treatment. That number can feel reassuring, but it is not helpful at the individual level, because for any given patient the outcome is binary — either the event happens or it does not, and the risk is not distributed evenly across the population. Patients with a personal or family history of depression, anxiety disorder, or attention-deficit disorder appear to be over-represented in the case reports, and clinicians typically choose alternative treatments for those patients when possible.

What to do practically:

The boxed warning is real information that should shape treatment decisions, but it is not a reason to stop montelukast that is currently working well without discussing the change with your prescriber. Abruptly stopping an asthma controller can precipitate an asthma exacerbation, and the risk of an uncontrolled asthma flare in a patient who has been well controlled on montelukast is not trivial. If you are on the medicine and worried about the warning, the right first step is a conversation, not a unilateral change.

Singulair reaches patients through four distinct oral formulations, each chosen to match the swallowing ability, taste tolerance, and physiology of a specific age group. All four deliver the same active molecule — montelukast sodium — and reach comparable systemic exposure once accounting for the dose. What changes is how the medicine arrives in the stomach: as a solid tablet swallowed whole, as a flavoured chewable disintegrated in the mouth, or as loose granules mixed into a spoonful of soft food. This section maps the four formats at a glance; the four sections after it drill into each one in practical detail.

Two practical points about this line-up are worth highlighting up front. First, the 4 mg chewable and the 4 mg granule packet share a strength but are not interchangeable at every age — a two-year-old with reliable chewing can use the tablet, but a fifteen-month-old on solid food should use the granules to avoid a choking risk. Second, when your child crosses an age threshold, the switch to the next-larger formulation is not automatic: it happens at a routine review with the prescriber, timed to a moment when the child's asthma is stable, so any effect of the change can be attributed to the transition rather than to a coincident flare.

Cipla and Sun Pharmaceutical Industries, the two Indian manufacturers behind most generic montelukast sold internationally, each produce all four formulations in facilities that supply regulated markets. The blister packs, the outer cartons, and the leaflets differ slightly between manufacturers, but the tablets and granules themselves are bioequivalent to the original Merck brand and to each other under the standards set by the relevant regulatory authorities.

The 10 mg film-coated tablet is the default formulation for anyone aged 15 years or older who needs Singulair for chronic asthma, allergic rhinitis, or exercise-induced bronchoconstriction. It is small, unscored, and pale in colour under both the original Merck branding and the Cipla and Sun Pharma generic labels. It is swallowed whole with water, without needing to be broken or crushed — the film coating is there to mask a mildly bitter taste that would otherwise linger.

The routine dosing story is straightforward:

Standard adult dose

One 10 mg tablet once daily. There is no titration up or down for average patients.

Timing

In the evening for chronic asthma or allergic rhinitis. For a pre-exercise dose taken as prevention of exercise-induced bronchoconstriction, at least two hours before planned exertion.

With or without food

Either. Food does not meaningfully change the amount of montelukast reaching the bloodstream.

Storage

Room temperature, protected from light and moisture; the original blister strip is fine.

A common practical question is whether the 10 mg tablet can be moved to a morning schedule. Some patients whose asthma symptoms are worst in the mid-day or early afternoon report better control on morning dosing, and clinicians sometimes suggest it as a small individualisation. The trial data supporting once-daily dosing were generated with evening administration, so if you are switching to morning dosing you should track your response for two weeks and confirm the change is helping rather than harming.

An unexpected but relevant point: the 10 mg tablet is one of the few asthma controller options available under generic pricing that requires no device, no coordination, no dose counter, and no spacer. That combination makes it valuable in settings where inhaler supplies or spacers are difficult to obtain, and it explains part of the drug's continued global use even as inhaled corticosteroids have become more affordable.

Children aged six through fourteen receive the 5 mg chewable tablet. The formulation is roughly twice the size of the 10 mg film-coated adult tablet, comes in a cherry flavour, and is designed to be crushed between the teeth and either chewed to a coarse texture or held in the mouth to disintegrate before swallowing. Neither approach affects how much montelukast reaches the bloodstream. Sun Pharma and Cipla generics produce this dose in colours and pack sizes that vary slightly between markets but are functionally identical.

The 5 mg chewable is also the option used for exercise-induced bronchoconstriction in children aged 6 to 14. In that use, the tablet is chewed at least two hours before planned exercise, and it is not added on top of a daily evening dose if the child is already taking Singulair for chronic asthma. The daily dose already provides receptor blockade over the exercise window.

Phenylketonuria families need to know that the 5 mg chewable contains phenylalanine as part of its sweetening system. The exact quantity is small — on the order of 0.7 mg per tablet in the original Merck formulation and comparable in the generic equivalents — but for a child with phenylketonuria this needs to be factored into daily phenylalanine allowance, and the metabolic dietitian looking after the child should be told about the medicine.

Parents sometimes ask whether the 5 mg chewable can be split for a smaller child. It should not be routinely split because the chewable is not scored for accurate halving and the sweetener distribution is not designed to remain uniform across a broken tablet. If a smaller dose is genuinely needed for a younger child, the 4 mg chewable or the 4 mg granule packet is the correct choice.

The 4 mg chewable is licensed for children aged two through five who can chew safely and reliably. This age range sits at the edge of where solid oral tablets are appropriate, and the decision between the 4 mg chewable and the 4 mg granule packet often comes down to how the individual child eats: a confident two-and-a-half-year-old who munches raisins without help can usually chew the tablet, while a cautious four-year-old with a history of gagging may still be better served by granules.

The mechanics of giving a 4 mg chewable are the same as for the 5 mg version: evening timing, supervised chewing, a sip of water afterwards. The tablet in this strength is slightly smaller than the 5 mg to make chewing easier for a smaller mouth, and it carries a similar cherry flavouring. Like the 5 mg version, it contains a small quantity of phenylalanine that families of a child with phenylketonuria need to know about.

A common question at this age is whether the tablet can be dissolved in a spoon of water instead of chewed. Dissolving in water is not the recommended handling for the chewable tablet — the granule packet is the formulation designed for dissolution and mixing. If the child refuses to chew, the correct switch is to the granule pack rather than an ad hoc dissolution attempt with the chewable.

The oral granules are the formulation of last resort for infants and toddlers who cannot chew safely. Each packet contains 4 mg of montelukast as small granules in a foil sachet. The pack is opened just before use, the granules are tipped into a spoonful of soft food or expressed breast milk or infant formula, and the whole spoonful is given to the child within 15 minutes of mixing. The granules should not be pre-mixed hours in advance and should not be dissolved into a bottle of liquid.

The minimum age depends on the indication in the local product label. In many jurisdictions the granules are approved from 6 months of age for perennial allergic rhinitis, from 12 months for asthma, and from 2 years for seasonal allergic rhinitis. The specific carton in your hand should be checked for the age threshold that applies in your country.

Because the granules are given in food and taste is largely masked, most infants and toddlers accept the dose without protest. If the child regularly refuses the food carrier or spits out the mixture, discuss alternatives with the prescriber — sometimes switching to a different carrier food or changing to the chewable tablet when the child is old enough resolves the difficulty.

Evening dosing is a small detail that carries an outsized clinical weight. The prescribing information specifies evening administration for chronic asthma prophylaxis in adults and children, and the registration trials that established efficacy were all designed with evening dosing. There is a biological reason for the timing, and it is worth understanding rather than treating as an arbitrary convention.

Asthma has a strong circadian rhythm. Symptoms are typically worst in the early hours of the morning — between roughly 2 a.m. and 6 a.m. — because of overnight fluctuations in airway inflammation, bronchial tone, and hormone levels including cortisol. Nocturnal awakenings from cough and wheeze are one of the most common reasons patients describe their asthma as poorly controlled. Allergic rhinitis also has a nocturnal peak in nasal congestion, disrupting sleep for perennial-rhinitis sufferers.

This alignment means the evening dose is doing its most useful work exactly when the airways are naturally at their tightest. Morning dosing would push the peak plasma level into the late morning or early afternoon, missing the nocturnal window that is the biggest source of symptoms for most asthma patients.

Two practical exceptions loosen the rule. First, if a patient reliably takes their evening dose but the timing must be moved forward or backward by a few hours because of work shifts or travel across time zones, keeping the dose within a broadly evening window is more important than hitting a specific hour. Second, some patients whose asthma is worst in the mid-day or early afternoon — a small minority — report better control on morning dosing, and clinicians can individualise the schedule if the two-week trial supports it.

The pre-exercise dose for exercise-induced bronchoconstriction is the one Singulair indication that does not follow an evening pattern. It is a single dose taken in the two-hour window before planned exertion, and it stands alone in patients who are not already on Singulair for asthma. This section walks through the practical scenarios in which the pre-exercise dose comes up and what to do in each one.

A common practical question: how well does the pre-exercise dose work compared with a short-acting inhaled beta-agonist taken 15-30 minutes before exercise? Head-to-head trials show that both approaches reduce the maximum fall in FEV1 during exercise, with the inhaled beta-agonist producing a faster and larger effect on average but the montelukast dose producing a more consistent effect across the exercise window and into recovery. Patients who choose montelukast typically do so because the inhaled option is impractical for their sport or lifestyle, because they respond less well to the inhaled option, or because they prefer an oral approach.

Athletes at the more serious end of competitive sport should also be aware that montelukast is not on the World Anti-Doping Agency prohibited list at the time of writing, and its use for a documented respiratory indication is not restricted in the same way that some inhaled beta-agonists are. However, anti-doping rules are updated annually, so athletes should check the most recent list rather than relying on an out-of-date summary before major competition.

Because Singulair is not a rescue medicine and its effects build over days to weeks rather than minutes, patients and parents often ask when they should expect to feel a difference. This section describes the practical timeline in a way that lines up with how the drug is used at home and what should count as a reasonable trial.

Two features of the timeline deserve emphasis. First, the drug does not need a loading dose — the first evening tablet is the same as every subsequent evening tablet, and there is no ramp-up phase. Second, the anti-inflammatory effect is complete after roughly two weeks; if symptoms have not improved at the four-week mark, they are unlikely to improve with more time on the drug, and the treatment plan should be re-examined.

Discontinuation follows a mirror-image timeline. Because the drug has a short plasma half-life, blood levels fall within a day of stopping, but receptor occupancy is lost more gradually over the following few days. Patients stopping Singulair after a period of good control should expect their asthma or rhinitis symptoms to return to baseline over roughly one to two weeks, not immediately. This is worth knowing when deciding whether to stop over a holiday or during a low-symptom season — the drop-off is not abrupt.

The decision about whether Singulair is doing its job should be made deliberately rather than by casual impression. Two to four weeks after starting the drug is the right moment to review because that is where the effect plateaus. Waiting longer risks continuing an ineffective medicine; deciding sooner risks abandoning one that would have worked. This section describes the metrics that matter and how to gather them without a lab visit.

Comparing week two or four against the baseline week before starting the drug is more meaningful than trying to remember what things were like a month ago. A simple three-column note on a phone — night awakenings, rescue puffs, activity limitation, one row per week — is enough to see whether the trend has shifted.

If the response looks like the pattern above at four weeks, continuing the drug is straightforward. If the response is unclear — slightly better but not obviously so — two more weeks of tracking sometimes clarifies the picture, particularly if the initial weeks coincided with a change in pollen levels, weather, or a viral illness that could have muddied the comparison.

Response should be reviewed at every subsequent appointment, not only at the initial four-week check. Asthma severity fluctuates over months and years, and a drug that helped clearly at the start can become less obviously useful later as other elements of the treatment plan change. It is entirely reasonable to test-stop Singulair after several months of stable control, following the same metrics, to see whether it is still adding value or whether the underlying disease is now controlled by other measures.

Not every patient responds well to Singulair. Population trial data show that about a third of asthma patients see a clear improvement, another third see a modest improvement that is easy to miss without tracking, and the remaining third do not benefit meaningfully. The reasons for individual variation are still being unpicked in research, but the practical response to a partial or absent effect is well established.

A four-week trial that shows no meaningful change on the metrics from the previous section is a clear signal to reconsider. The response options are not one-size-fits-all — they depend on why the patient was started on Singulair, whether they have an alternative that fits their circumstances, and how comfortable they are with a change.

Which patients respond and which do not is not fully predictable from the outside. There are hints from research: patients whose asthma has a strong allergic component and elevated eosinophils tend to respond better, patients whose asthma is dominated by neutrophilic inflammation or by aspirin sensitivity often respond better than average as well, and patients whose asthma flares are viral in trigger tend to respond less to leukotriene blockade. But none of these predictors are strong enough to justify skipping a trial in a patient who has a good reason to try the oral option.

Stopping Singulair after a failed trial is generally straightforward. Because the plasma half-life is short and the anti-inflammatory effect wanes over roughly one to two weeks after discontinuation, symptoms will return to baseline in that window if the drug had been providing any benefit. A rebound worsening of symptoms — symptoms becoming worse than before starting — is not a recognised feature of montelukast discontinuation.

Most patients tolerate Singulair well. Common side effects are usually mild, self-limiting, and settle in the first two to three weeks of use. The list below reflects the pooled placebo-controlled trial data submitted for the drug's registration and the accumulated post-marketing experience, ordered by rough frequency in the ambulatory adult and paediatric population. Rare and serious reactions are discussed in the sections that follow rather than buried in a long list here.

Two features of the common side-effect picture are worth understanding. First, the placebo-versus-active difference in most of these categories is modest — a fair proportion of the events reported on Singulair also occurred on placebo. That is why the drug is generally considered well tolerated: the increment over background is small. Second, most common side effects settle within the first two to three weeks as the body adapts to the medicine; symptoms that persist beyond a month often reflect something else and are worth investigating.

The frequency ranking above should not be over-interpreted. Any individual patient can experience any of these reactions, and rare reactions do occur. If a side effect appears within the first few weeks and it is troubling but not in the red-flag category, keeping a short daily note about when it happens and how severe it is makes the follow-up conversation with the prescriber more useful than trying to describe it from memory.

Section 11 laid out the FDA boxed warning and its rationale. This section is the practical companion: how to actually monitor for neuropsychiatric symptoms at home, week by week, in a way that is realistic for a working parent, an adult patient, or an older adolescent taking Singulair on their own. Monitoring that only exists on paper is worse than no monitoring at all — it creates the illusion of safety without the substance.

A good home-monitoring routine has three properties. It is lightweight enough to survive daily life, it produces observations someone else could verify, and it names a specific action when a threshold is crossed. What follows is a routine that meets all three tests in most households.

The three-minute weekly check is not a diagnostic tool. It exists to catch a trend early so the medicine can be re-evaluated before a small change becomes a distressing one. Most weeks the answer to every question will be nothing worth noting, and that is the intended outcome — the point is not to find problems but to be sure they have been asked about.

Two adjustments are worth making in specific households. For families with a child who has an existing attention-deficit or anxiety diagnosis, the weekly check should be more attentive because the child's baseline is already noisy; changes in that baseline are what matter. For adults with a history of depression or other mental-health condition, the weekly check should be done with a family member or partner — self-observation during a low mood is unreliable, and an outside observer catches things the patient will minimise or miss.

Montelukast is metabolised almost entirely by the liver, so it is reasonable to ask whether the drug can harm the liver. The short answer is that clinically important hepatic effects are uncommon but real, and the pattern in reported cases is worth knowing so that early signals can be picked up before they become serious. Routine baseline liver function testing before starting Singulair is not recommended for most patients, and routine repeat testing during treatment is also not standard practice.

For most patients the practical implication is simple: no monitoring blood tests are needed, but symptoms suggestive of liver trouble should be taken seriously if they appear. Yellowing of the whites of the eyes or of the skin, dark tea-coloured urine, right upper abdominal pain lasting more than a day, unusual persistent nausea, or noticeable itching without a rash are all reasons to contact the prescriber. In these situations liver function tests will usually be requested, and if the pattern points at the drug, Singulair is stopped and an alternative asthma or rhinitis treatment is arranged.

Mild to moderate hepatic impairment — Child-Pugh Class A or B — does not by itself require a dose reduction of montelukast, according to the product labelling. Severe hepatic impairment, which is uncommon in the ambulatory asthma population, warrants a case-by-case conversation with the prescribing clinician; the trial data in that group are limited and other controllers may be preferred.

Churg-Strauss syndrome, now formally called eosinophilic granulomatosis with polyangiitis, is a rare form of systemic vasculitis that mostly affects patients with severe or difficult-to-control asthma. It has been reported in patients taking montelukast, but the relationship is not straightforward and understanding it properly avoids both false alarm and false reassurance.

The clinical picture of eosinophilic granulomatosis with polyangiitis typically includes three overlapping phases:

Phase 1 — Prodromal asthma and allergic rhinitis

Adult-onset asthma with prominent nasal polyps or allergic rhinitis, often difficult to control despite several controllers. This phase can last years before anything else appears.

Phase 2 — Peripheral blood eosinophilia and tissue infiltration

Rising eosinophil counts on routine blood tests; eosinophilic infiltration of the lungs producing new or worsening pulmonary symptoms; sometimes gastrointestinal or skin involvement.

Phase 3 — Systemic vasculitis

Small-vessel vasculitis affecting the peripheral nerves (mononeuritis multiplex — numbness or weakness in a hand or foot), the heart, the kidneys, and the skin. This phase is the one that carries meaningful morbidity and demands prompt recognition.

The controversy around montelukast concerns whether the drug causes the syndrome or merely unmasks it. The prevailing interpretation, based on case series and pharmacovigilance reviews, is that most reported cases occurred in patients who already had underlying eosinophilic disease that was being partly suppressed by oral corticosteroids. When Singulair was added and steroid doses were reduced, the previously suppressed vasculitis became clinically evident. That mechanism — steroid withdrawal unmasking — does not indicate that montelukast causes the disease, but it does mean that patients being tapered off oral steroids as Singulair is added should be watched for the syndrome.

The absolute frequency of eosinophilic granulomatosis with polyangiitis in the montelukast-treated population is very low — on the order of one in tens of thousands of patient-years. That is not a reason for baseline blood eosinophil monitoring in every patient starting the drug. It is a reason for the treating team to recognise the syndrome quickly when its features do appear, and for patients to know the red-flag list so they can flag it rather than dismiss it as a bad flu.

Montelukast has a relatively clean drug-interaction profile compared with many other chronic medications, but a small number of clinically important interactions are worth knowing about. The interaction landscape falls into three broad groups: interactions that meaningfully change montelukast levels, interactions in which montelukast affects other drugs, and interactions that are theoretical rather than observed.

Two features of this table are worth internalising. First, most of the drugs a patient with asthma or allergic rhinitis is likely to be taking — inhaled steroids, beta-agonists, antihistamines, intranasal steroids — do not interact meaningfully with montelukast. The drug is easy to layer into a treatment plan without pharmacokinetic worry. Second, the drugs that do matter for interaction — gemfibrozil, phenobarbital, phenytoin, rifampin — are ones the patient is likely to know about because they are prescribed for specific chronic conditions and are usually managed by a specialist.

Strong hepatic enzyme inducers are worth their own section because the interaction is quantitatively larger than most drug-drug effects with Singulair and because the patients likely to be on these medicines — adults on chronic anti-epileptic therapy, patients on rifampin-based tuberculosis regimens — are otherwise excellent candidates for a simple oral asthma controller.

Product labelling does not currently recommend a dose adjustment of montelukast in patients on strong hepatic enzyme inducers. Two practical approaches are used in clinical care:

A related and less obvious interaction is with St John's wort, a widely used over-the-counter herbal preparation that induces the same hepatic enzymes, if more modestly. Regular St John's wort use should be disclosed at the appointment where Singulair is prescribed, and its impact should be borne in mind if the drug seems to be working less well than expected.

Decisions about montelukast during pregnancy, breastfeeding, and family planning follow a careful risk-benefit conversation because the drug crosses the placenta and appears in breast milk, while the underlying asthma or allergic rhinitis being treated also carries its own risks to a pregnancy if left uncontrolled. The following sections summarise what is known and how the discussion is usually framed with a patient.

The practical positioning in pregnancy: montelukast is generally considered acceptable when it is genuinely needed for asthma control and where the alternatives have failed or are not tolerated. Inhaled corticosteroids remain the preferred controller for pregnant patients with persistent asthma, based on decades of accumulated obstetric safety data. Montelukast is a reasonable second-line or add-on choice when the inhaled option alone is insufficient or unusable, and its use should be discussed with the obstetric team, particularly given the boxed warning about neuropsychiatric events in the context of pregnancy-related mood changes.

In allergic rhinitis during pregnancy, montelukast is less easy to justify given the availability of intranasal saline, intranasal corticosteroids, and locally acting antihistamines, all with reassuring pregnancy safety profiles. The 2020 FDA boxed warning specifically advised reserving montelukast for allergic rhinitis when other treatments have failed, and pregnancy is a setting where that guidance carries particular weight.

Uncontrolled asthma during pregnancy is a serious risk to both mother and fetus — hypoxia during a severe exacerbation is much more dangerous than most of the medicines used to control the disease. Patients whose asthma has been well controlled on Singulair and who become pregnant should not stop the drug abruptly without discussing the change with their obstetric and asthma teams.

Older adults are a growing proportion of the asthma and allergic rhinitis population, and montelukast is often attractive in this group precisely because it avoids the inhaler-technique challenges that make inhaled therapy difficult. There are two questions that come up routinely: does the elderly patient need a different dose, and does kidney function influence prescribing?

Two nuances become more relevant with age. First, the boxed warning about neuropsychiatric events applies to older adults exactly as it applies to any other age group, and the older adult population already has a higher baseline rate of depression, sleep disturbance, and cognitive change. Distinguishing a drug effect from an age-related change requires the same kind of attentive weekly check described in section 23, ideally with a family member or partner as an observer.

Second, the elderly are more likely to be on multiple chronic medications, and every additional medicine widens the surface area for drug interactions. The interaction table in section 26 should be checked against the full current medication list, not just the ones that seem obviously relevant to breathing or allergy.

Practical caregivers of elderly patients living independently often find that pairing the Singulair dose with an established evening routine — brushing teeth, a specific television programme, closing the shutters — produces more reliable adherence than any pill reminder alarm. Reliable adherence is the largest single factor in whether the drug produces its expected benefit, and it is more important than any pharmacokinetic subtlety at this stage of life.

Singulair has a short and clean contraindication list. There is one absolute contraindication and a small number of relative contraindications where the drug can be used but with careful thought about whether an alternative would serve the patient better. Understanding the difference between an absolute and a relative contraindication is the point of this section: an absolute one is a stop, a relative one is a pause for reflection.

Relative contraindications are situations where prescribing Singulair calls for a specific conversation and often for a different first-line choice. None of these situations forbid the drug outright — they weight the decision.

Two contraindications are frequently misunderstood and are worth explicit correction. Kidney impairment, even at end-stage requiring dialysis, is not a contraindication because montelukast is not renally cleared. Long-term oral corticosteroid use is not a contraindication either; the two are commonly used together in difficult asthma, though the Churg-Strauss vasculitis unmasking discussed in section 25 means that a steroid taper alongside Singulair use deserves monitoring.

Singulair storage is straightforward, but the handling detail differs between the tablet, the chewable, and the granule packet. This section brings the practical differences together so the medicine is used the way the manufacturer intended and the way trial evidence assumed.

Two ambient conditions are the enemies of the tablet forms: high humidity and direct sunlight. A bathroom cabinet is a poor choice because of the moisture from showering. A kitchen cupboard away from the stove is a better one. A pill organiser is fine for a week's worth of adult tablets but should not be used to store months of medicine outside the blister, because the film-coated tablet can absorb moisture from ambient air over time.

Expiration dates are printed on the outer carton and on the blister strip. A tablet that is a few weeks past expiration is unlikely to be dangerous, but its content of active drug can be lower than intended, and a controller that is under-dosed produces the disappointing partial response described in section 21. Replacing an expired supply is the reliable choice.

A missed dose is a common occurrence over the months and years of chronic therapy, and how it is handled matters less than most patients assume. Because montelukast has short plasma half-life but long receptor occupancy, a single missed evening dose does not usually cause a noticeable loss of asthma or rhinitis control. Repeated missed doses are a different matter, and this is where the drug's benefit begins to erode.

Travel is a specific missed-dose risk, and one that can be planned around. Two situations come up in practice. First, a trip across time zones needs a decision about which local time counts as evening. The pragmatic approach is to shift the dose gradually over the trip, taking each night's dose in whatever counts as evening at the destination, rather than trying to hold to the original home time zone. The one-to-two-hour drift over a week does not undermine efficacy.

Second, a trip where the medicine will not be practical to carry at the usual evening time — a wedding, a day-long outdoor event, a long-haul flight — can be handled by taking the dose earlier or later within a broad evening window, or occasionally skipping a single night and resuming the following evening. Neither approach damages long-term control.

For patients using the granule packets for an infant, travel involves an additional consideration: a spoon and a small container of the child's usual carrier food (applesauce, mashed banana) should be part of the day-bag if evening will be spent away from home. Improvising with an unfamiliar food often results in a partly refused dose, and repeated partial doses over a week of travel add up to real loss of control.

Singulair sits in an unusual category of medicine where the decision to start it is more a conversation than a prescription. Because the boxed warning demands informed consent, because the alternatives are real, and because the drug's benefit varies substantially between patients, the appointment where Singulair is first proposed — or the one where an existing prescription is reviewed — is a place to be well prepared. This section suggests the questions to bring and the notes to take home.

Not every appointment will have time for all six questions. If time is tight, the boxed-warning discussion and the baseline documentation are the two most important. Everything else can be revisited at the follow-up.